Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CalciMedica Inc. stock logo
CALC
CalciMedica
$0.66
-3.4%
$0.64
$0.46
$7.20
$10.38M0.85135,032 shs237,629 shs
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$3.36
-7.2%
$3.62
$1.08
$17.18
$41.06M2.57524,512 shs441,230 shs
LITS
Lite Strategy
$1.17
-4.1%
$1.17
$0.95
$9.00
$39.81M0.25327,052 shs651,397 shs
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$5.22
-9.7%
$5.39
$2.12
$11.98
$39M1.49143,830 shs257,621 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CalciMedica Inc. stock logo
CALC
CalciMedica
0.00%+4.47%+7.72%+0.31%-65.65%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
0.00%-6.67%-14.07%-18.84%+184.75%
LITS
Lite Strategy
0.00%-4.10%-0.85%+4.46%+116,999,900.00%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
0.00%-19.44%+16.52%+32.49%+521,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CalciMedica Inc. stock logo
CALC
CalciMedica
$0.66
-3.4%
$0.64
$0.46
$7.20
$10.38M0.85135,032 shs237,629 shs
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$3.36
-7.2%
$3.62
$1.08
$17.18
$41.06M2.57524,512 shs441,230 shs
LITS
Lite Strategy
$1.17
-4.1%
$1.17
$0.95
$9.00
$39.81M0.25327,052 shs651,397 shs
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$5.22
-9.7%
$5.39
$2.12
$11.98
$39M1.49143,830 shs257,621 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CalciMedica Inc. stock logo
CALC
CalciMedica
0.00%+4.47%+7.72%+0.31%-65.65%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
0.00%-6.67%-14.07%-18.84%+184.75%
LITS
Lite Strategy
0.00%-4.10%-0.85%+4.46%+116,999,900.00%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
0.00%-19.44%+16.52%+32.49%+521,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CalciMedica Inc. stock logo
CALC
CalciMedica
2.00
Hold$10.001,421.84% Upside
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
2.25
Hold$5.8874.85% Upside
LITS
Lite Strategy
1.00
SellN/AN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CALC, LITS, HYPD, and TAOX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2026
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
Reiterated RatingSell (D-)
4/9/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
UpgradeStrong-Buy
3/30/2026
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
DowngradeHoldStrong Sell
3/5/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Lower Price TargetOutperform$20.00 ➝ $10.00
(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CalciMedica Inc. stock logo
CALC
CalciMedica
N/AN/AN/AN/A($0.07) per shareN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$810K50.69N/AN/A$4.73 per share0.71
LITS
Lite Strategy
$65.30M0.61$5.85 per share0.20$1.67 per share0.70
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
$300K129.98N/AN/A$3.11 per share1.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CalciMedica Inc. stock logo
CALC
CalciMedica
-$29.56M-$1.31N/AN/AN/AN/A-1,093.51%-144.33%N/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$45.31M-$11.80N/A1.58N/AN/A-95.63%-75.00%N/A
LITS
Lite Strategy
-$15.94M-$1.33N/AN/AN/AN/A-90.81%-89.33%N/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
-$28.74M-$12.78N/AN/AN/AN/A-163.40%-133.47%N/A

Latest CALC, LITS, HYPD, and TAOX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q3 2026
LITS
Lite Strategy
N/A-$0.66N/A-$0.66N/AN/A
5/13/2026Q1 2026
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/A$0.43N/A$0.43N/A$5.96 million
3/31/2026Q4 2025
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/A$1.03N/A$1.03N/A($2.46) million
3/26/2026Q4 2025
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/A-$7.76N/A-$7.76N/A$0.50 million
3/3/2026Q4 2025
CalciMedica Inc. stock logo
CALC
CalciMedica
N/A-$0.69N/A-$0.69N/AN/A
2/17/2026Q2 2026
LITS
Lite Strategy
N/A-$0.82N/A-$0.82N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CalciMedica Inc. stock logo
CALC
CalciMedica
N/AN/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/AN/AN/AN/AN/A
LITS
Lite Strategy
N/AN/AN/AN/AN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CalciMedica Inc. stock logo
CALC
CalciMedica
N/A
1.61
3.58
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
0.19
2.68
2.68
LITS
Lite Strategy
N/A
11.53
10.04
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
N/A
27.39
13.99

Institutional Ownership

CompanyInstitutional Ownership
CalciMedica Inc. stock logo
CALC
CalciMedica
N/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
25.84%
LITS
Lite Strategy
52.38%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
10.34%

Insider Ownership

CompanyInsider Ownership
CalciMedica Inc. stock logo
CALC
CalciMedica
41.55%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
7.50%
LITS
Lite Strategy
1.60%
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
2.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
CalciMedica Inc. stock logo
CALC
CalciMedica
3015.80 million9.23 millionNo Data
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
4012.22 million11.30 millionNo Data
LITS
Lite Strategy
10034.03 million33.48 millionN/A
Synaptogenix, Inc. stock logo
TAOX
Synaptogenix
47.47 million7.27 millionN/A

Recent News About These Companies

Synaptogenix (NASDAQ:TAOX) Rating Increased to Hold at Wall Street Zen
TAO Synergies Announces $11 Million Private Placement
Synaptogenix Unveils TAO-Focused Crypto Treasury Plan
Synaptogenix Inc Ordinary Shares

New MarketBeat Followers Over Time

Media Sentiment Over Time

CalciMedica stock logo

CalciMedica NASDAQ:CALC

$0.66 -0.02 (-3.37%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$0.64 -0.01 (-1.99%)
As of 05/15/2026 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Hyperion DeFi stock logo

Hyperion DeFi NASDAQ:HYPD

$3.36 -0.26 (-7.18%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$3.40 +0.04 (+1.19%)
As of 05/15/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Lite Strategy NASDAQ:LITS

$1.17 -0.05 (-4.10%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$1.16 -0.01 (-1.28%)
As of 05/15/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Synaptogenix stock logo

Synaptogenix NASDAQ:TAOX

$5.22 -0.56 (-9.69%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$4.99 -0.23 (-4.35%)
As of 05/15/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.